Skip to content

Application of Large Volume Acute Normovolemic Hemodilution in Cardiac Valve Surgery

Effect of Large Volume Acute Normovolemic Hemodilution on Perioperative Blood Transfusion and Outcomes in Cardiac Valve Surgery

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03933917
Enrollment
74
Registered
2019-05-01
Start date
2019-05-27
Completion date
2020-04-22
Last updated
2020-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Valve Surgery

Brief summary

The application of acute Normovolemic Hemodilution in cardiac surgery can effectively reduce perioperative blood transfusion, reduce postoperative complications and mortality, and is a low-cost, operable and effective blood protection measure.For the application of Acute Normovolemic Hemodilution in heart surgery, we still face an urgent problem: to what extent can Acute Normovolemic Hemodilution achieve better blood saving effect, that is, whether a large number of Acute Normovolemic Hemodilution can reduce perioperative blood transfusion to a greater extent.

Interventions

Following induction of anesthesia, the volume of blood to be removed during Acute Normovolemic Hemodilution was calculated using an established formula:V=Weight(Kg)×12-15(mL/Kg);Blood to be removed was capped at: Vmax=EVB×(Hi-Hf)/Hav(EBV= estimated blood volume (male:70mL/Kg,female:65mL/Kg);Hi= initial hemoglobin ;Hf=target Hb( 10g/dL );Hav= the average of the initial and minimal allowable hemoglobin).Ensure the volume of removed blood does not exceed the upper limit and Hb ≥10g/dL after blood removed.

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Audlt patients ( ≥ 18 years old); 2. elective valve surgery under cardiopulmonary bypass; 3. Preoperative hemoglobin (Hb) ≥ 12g/dl; (4) Transfusion Risk Understanding Scoring Tool (TRUST) ≥ 2 (possibility of blood transfusion ≥40%).

Exclusion criteria

(1)Low body weight (male: \<50 kg;Female: \< 45kg);(2)preoperative shock;(3)myocardial infarction within 3 months before surgery;(4)ischemic heart disease;Left main coronary artery stenosis \>70%;Severe aortic stenosis (area \< 0.7cm2);Severe changes in left ventricular function (ejection fraction \<30%, requiring vasoactive agents to assist circulation);(5)uncontrolled hypertension;(6) severe carotid artery stenosis (\>70% or with symptoms);(7) kidney failure (blood creatinine level \>442 mmol/L) or dialysis treatment;(8) serum albumin level (ALB) is less than 25 g/L.(9) international standardized ratio (INR) \>1.5 or platelet count \<100 103/mm3;(10)Inherited/acquired coagulation function defect;(11)preoperative preparation platelet;(12) contagious or infectious diseases;(13) patient or family members refused to participate in research;(14)refused to infusion of autologous blood or allogeneic blood products

Design outcomes

Primary

MeasureTime frameDescription
Enrollment rate of subjectsThrough study completion,about 8 monthsThe percentage of patients who completed the study
Completion rate of acute normovolemic hemodilutionThrough study completion,about 8 monthsThe percentage of patients who complete large volume of acute normovolemic hemodilution
Additional blood transfusion beyond transfusion protocolThrough study completion,about 8 monthsNonstandard blood transfusion

Secondary

MeasureTime frameDescription
Rate of postoperative neurological complicationThrough study completion,about 8 monthsIncluding cerebral hemorrhage, cerebral infarction according to physical and laboratory examination
Rate of perioperative blood transfusionThrough study completion,about 8 monthsThe percentage of red blood, fresh frozen plasma and platelet transfusion
Other severe complicationThrough study completion,about 8 monthsIncluding re-operation, re-admission of intensive care unit, multiple organ dysfunction, all cause death according to physical and laboratory examination and medical record
Rate of postoperative renal complicationThrough study completion,about 8 monthsNeed renal replacement therapy
Rate of postoperative cardiac complicationsThrough study completion,about 8 monthsIncluding myocardial infarction, heart failure, low cardiac output, pericardial tamponade, severe arrhythmia according to physical and laboratory examination
Rate of postoperative pulmonary complicationsThrough study completion,about 8 monthsIncluding moderate and massive pleural effusion, respiratory failure, re-intubation according to physical and laboratory examination

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026